The minimal metabolism of SGLT-2 inhibitors, coupled with their renal elimination, also suggests a lower risk of drug interactions and potential toxicity, which is especially important in the elderly population often affected by Alzheimer’s disease [61]. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.